Forefront Analytics, LLC
- SEC CIK
- 0001696802
- Latest filing
- Aug 12, 2026
Holdings changes from Q4 2023 to Q1 2024
Long positions only; new, added, reduced and sold out are based on share counts. Pick any two quarters this institution filed.
- New
- 3
- Est. +$15.7M
- Added
- 29
- Est. +$1.25M
- Reduced
- 34
- Est. −$16.1M
- Sold out
- 3
- Est. −$4.94M
Portfolio value went from $202.6M to $206.2M (+$3.68M (+1.8%)); positions from 67 to 67 (0).
All Q1 2024 holdingsAll Q4 2023 holdings
In the shares, value and % of portfolio columns, the top figure is Q1 2024 and the gray one below is Q4 2023. For stocks that split between the two quarters, Q4 2023 shares are converted at the split ratio before comparing.
| Security | Action | Shares | Share change | Value | Est. bought or sold | % of portfolio | Weight change (pp) |
|---|---|---|---|---|---|---|---|
| TVTXTravere Therapeutics, Inc. | NewHistory | 12,0800 | +12,080 | $93.1K$0 | +$93.1K | <0.1%0.0% | +0.05 |
| ALXOAlx Oncology Holdings Inc | NewHistory | 10,2610 | +10,261 | $114.4K$0 | +$114.4K | 0.1%0.0% | +0.06 |
| Nushares ETF Tr67092P300 | New– | 399,2840 | +399,284 | $15.5M$0 | +$15.5M | 7.5%0.0% | +7.52 |
Estimated amounts multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares): new positions use this quarter's value and sold-out positions last quarter's; positions reported only as principal (PRN) cannot be estimated. 13F shows only quarter-end holdings, not when trades happened or at what price.